Drugs / Alisporivir
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02173574 | Aug → Nov 2014 | hepatitis C virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01975337 | Aug 2013 → Feb 2014 | chronic renal failure syndrome | Debiopharm International SA | Completed | No outcome recorded |
| Phase 1 | NCT01860326 | Mar → Sep 2011 | liver disorder | Debiopharm International SA | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04608214 | Jan 2021 → Jan 2022 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02094443 | Mar 2014 → Apr 2015 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| Phase 2 | NCT01215643 | Oct 2010 → May 2012 | chronic hepatitis C virus infection, chronic pain syndrome | Debiopharm International SA | Completed | No outcome recorded |
| Phase 2 | NCT01183169 | Aug 2010 → May 2013 | hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| Phase 2 | NCT00537407 | Sep 2007 → Apr 2010 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01500772 | Mar → May 2012 | hepatitis C virus infection | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 3 | NCT01446250 | Dec 2011 → May 2013 | chronic hepatitis C virus infection | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 3 | NCT01318694 | Mar 2011 → Aug 2013 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01970904 | Oct 2013 → Mar 2015 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| — | NCT00854802 | Jan 2009 → Sep 2010 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02753699 Background | Dec 2011 → May 2015 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-01-18 | Debiopharm International SA | Phase II Research Against Covid-19 Launched in France with Debiopharm’s Antiviral Alisporivir debiopharm.com ↗ |
| 2015-09-08 | Debiopharm International SA | Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio025) in muscular dystrophy. debiopharm.com ↗ |
| 2015-01-12 | Debiopharm International SA | Debiopharm Group regains full rights to Alisporivir program debiopharm.com ↗ |
| 2014-08-07 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals’ HCV NS5A Inhibitor EDP-239 Advances into Combination Studies with Alisporivir (DEB025) enanta.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alisporivir | “Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to...” NCT01318694 ↗ |
| Known as | (d-meala)3-(etval)4-csa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651956 ↗ |
| Known as | ALV | “This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin...” NCT01500772 ↗1“This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African...” NCT01446250 ↗ |
| Known as | DEB025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02173574 ↗ |
| Known as | Debio 025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00854802 ↗ |
| Known as | UNIL 025 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651956 ↗ |
| Action | Inhibit | “Cyclophilin A inhibitor” CHEMBL1651956 ↗1“cyclophilin inhibitor” NCT00537407 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1651956 ↗ |
| Route | Oral | “Debio 025 (alisporivir) 400 mg orally once daily” NCT00537407 ↗ |
| Target | PPIA | “Cyclophilin A inhibitor” CHEMBL1651956 ↗ |